John D. Scott, MD, MSc
Department of Medicine, Division of Allergy & Infectious Diseases
Medical Director, Digital Health
Medical Director, Liver Clinic, Harborview Medical Center
Adjunct Professor, Family Medicine
Sites of Practice: 
Harborview Medical Center
University of Washington Medical Center

Faculty Information


Dr. Scott's research focuses on viral hepatitis and the use of telehealth technologies to improve care of patients with Infectious Disease issues. Dr. Scott has an active research program with novel antivirals and diagnostics, in partnership with pharmaceutical companies. Along with Public Health Seattle King County, he is working on a CDC-funded initiative to increase diagnosis, linkage to care and treatment of patients with hepatitis C.

In 2009, he launched Project ECHO in Washington State. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of hepatitis C, HIV/AIDS and tuberculosis. In 2013, he became the first medical director for telehealth at the UW. Research has focused on creating innovative learning platforms, in partnership with Dr. David Spach and Dr. Nina Kim through HCV Online.

AOA, Georgetown University School of Medicine
Fellow, IDSA
Seattle Met, Top Doctors
Warren Featherstone Reid Award for Excellence in Health Care for Washington State
(206) 744-3393
Mailing Address: 

Harborview Medical Center

325 9th Ave

Box 359938

Seattle, WA 98104

Research & Clinical Interests
Research Interests: 
  • Viral hepatitis
  • Infections in solid organ transplant recipients
  • Telemedicine
Clinical Interests: 
  • Viral hepatitis
  • Infections in solid organ transplant recipients
  • Telemedicine

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014 Nov 15; 384(9956):1756-65
• PubMed Abstract ]

Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and HCC in patients with HIV infection. Hepatology. 2013; 57:249-57. 
• PubMed Abstract

Scott JD, Unruh K, Catlin MC, et al. Project ECHO: A model for complex, chronic care in the pacific northwest of the United States. J Telemed Telecare. 2012; 18(8):481-4. 
PubMed Abstract

Coffin P, Scott JD, Sullivan S, Golden M. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012 May; 54(9):1259-71.
PubMed Abstract

Schiffer JT, Scott JD, Corey L. Fighting a defiant virus. Nature Med. 2011; 17:253-4.
Nature Medicine Abstract

Scott JD, Holte S, Urban T, Burgess C, Coppel E, Wang C, Corey L, McHutchison J, Goldstein D.; IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult to treat hepatitis C virus infection. J Infect Dis. 2011; 204:419-25.
• PubMed Abstract

Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: A systematic review. JAMA. 2007; 297:724-732.
• PubMed Abstract